Sat, Aug 30, 2014, 10:06 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

zero.risk13 51 posts  |  Last Activity: Aug 21, 2014 10:04 AM Member since: Oct 12, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    House cleaning begins, great news for investors

    by johnlaw0077 Aug 21, 2014 9:56 AM
    zero.risk13 zero.risk13 Aug 21, 2014 10:04 AM Flag

    There's a lot more house cleaning that needs to be done.

  • zero.risk13 zero.risk13 Aug 21, 2014 10:03 AM Flag

    What about some of the investors who made money with Madoff?
    Guess what, they had to disgorge those illicit gains.

  • zero.risk13 zero.risk13 Aug 21, 2014 10:01 AM Flag

    What about the investors who bought the shares that the insiders dumped at $5+, idiot?

  • zero.risk13 by zero.risk13 Aug 21, 2014 9:59 AM Flag

    * PMA filed .... approval expected around year end.
    * GTHP's biophotonic cervical cancer scan is already approved in EU, Canada, Mexico, Singapore....
    * Over 60M pap smear tests are taken annually in the US alone.
    * GTHP's scan is more accurate and produces instant test results, no lab analysis needed.
    * International sales are ramping up.
    * the new CEO is from GE Diagnostics and Abbott Healthcare

    You don't ned to pay Yellen inflated bubble prices for a biotech.
    GTHP's market cap is only $30M.

    EXAS which has a pooper scooper scan for colorectal cancer, approved recently, is at a market cap of $1.7 BILLION

  • Over 60 million pap smear tests are taken annually in the US.
    It's an invasive procedure that requires a swab being sent to a lab for analysis.
    GTHP developed a biophotonic scan which produces instant test results.

    The scan is already approved in the EU, Canada, Mexico, Singapore .......
    FDA approval expected in the Dec. - Jan. time period will send the stock rocketing.
    The time to load up is now.

  • Reply to

    Time to Switch to GTHP Before All is Lost Here

    by gthp10bagger Aug 13, 2014 11:14 AM
    zero.risk13 zero.risk13 Aug 14, 2014 9:59 AM Flag

    BoooHooooo, where does it hurt?
    Alleviate the pain .......... GTHP will soon be higher priced ........ that's a quick triple.

  • Reply to

    Switch to GTHP ..... CC Tomorrow

    by gthp10bagger Aug 13, 2014 11:06 AM
    zero.risk13 zero.risk13 Aug 14, 2014 9:56 AM Flag

    Good looking stock.

  • zero.risk13 by zero.risk13 Aug 6, 2014 9:15 AM Flag

    Guided Therapeutics, Inc. (GTHP) (GTHP), the maker of the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly at the point of care, today announced the appointment of Gene Cartwright, 59, as Chief Executive Officer, effective January 6, 2014. Mr. Cartwright replaces Mark L. Faupel, who has transitioned to the role of Chief Scientific Officer.

    “Gene has great experience in the diagnostics market both in the development and introduction of new diagnostics technologies as well as extensive successful commercial experience with global businesses,” said Michael James, Chairman of the Board of Directors for Guided Therapeutics. “The company is poised for accelerated growth and we are confident that Gene is the right person to move the company forward.”

    Gene brings over 30 years of experience working in the IVD diagnostics industry. He joins Guided Therapeutics from Omnyx, LLC, a Joint Venture between GE Healthcare and the University of Pittsburgh Medical Center, where, as CEO for over four years he founded and managed the successful development of products for the field of Digital Pathology.

    Prior to his work with Omnyx, LLC, he was President of Molecular Diagnostics for GE Healthcare. Prior to GE, he was Divisional Vice President/General Manager for Abbott Diagnostics’ Molecular Diagnostics business. In his 24 year career at Abbott, he also served as Divisional Vice President for U.S. Marketing for five years.

    “I’m very excited to join Guided Therapeutics at this critical stage in the company’s history,” Mr. Cartwright said. “They have introduced their CE Marked LuViva product internationally and I look forward to growing the sales for this important new global product in the cervical cancer diagnostics market. I also will work diligently to achieve FDA approval for LuViva in the U.S. and build on the great work that has been done to date by Mark Faupel and the Guided Therapeutics team.”

  • Reply to

    oncs

    by bausin6 Aug 5, 2014 12:11 PM
    zero.risk13 zero.risk13 Aug 5, 2014 12:36 PM Flag

    Solar stocks are the latest tulip stocks. You will get crushed. This is an excellent time to sell and load up on GTHP.

  • zero.risk13 by zero.risk13 Aug 4, 2014 12:08 PM Flag

    You could be riding a stallion instead of a broken down nag.

  • Reply to

    Burn rate?

    by tdhand2003 Aug 4, 2014 10:34 AM
    zero.risk13 zero.risk13 Aug 4, 2014 10:46 AM Flag

    Switch to GTHP.
    You can sell, take a tax loss and roll over the proceeds into GTHP.
    Approved trumps years away from a product, if ever.

    The HPV scan market is huge.
    Over 60M pap smear test are taken annually in the US alone.
    GTHP's biophotonic technology is more accurate and produces instant test results (swabs don't need to be sent to a lab).

    At a $30M market cap, the potential gains on the stock are astronomical.

  • Reply to

    good call whoever said .40 cents

    by lopopswz Aug 4, 2014 10:18 AM
    zero.risk13 zero.risk13 Aug 4, 2014 10:43 AM Flag

    You can sell, take a tax loss and roll over the proceeds into GTHP.
    Approved trumps years away from a product, if ever.

    The HPV scan market is huge.
    Over 60M pap smear test are taken annually in the US alone.
    GTHP's biophotonic technology is more accurate and produces instant test results (swabs don't need to be sent to a lab).

    At a $30M market cap, the potential gains on the stock are astronomical.

  • zero.risk13 by zero.risk13 Aug 1, 2014 12:37 PM Flag

    Now that's a stock!

  • $35M market cap
    An approved product (in the EU, Canada, Mexico....) for a huge market.
    PMA submitted to FDA for US approval.
    First in class patented biophotonics technology.
    A new CEO marketing whiz formerly with Abbott Healthcare and GE Diagnostics.

    Everyhthing is lined up for huge gains.
    Buy now and retire a $millionaire in few years.

  • Reply to

    Consider This

    by zero.risk13 Jul 30, 2014 5:58 PM
    zero.risk13 zero.risk13 Jul 30, 2014 6:29 PM Flag

    Consider this .... a proven and approved potential blockbuster product trumps nothing close to being approved, and at 1/4 the market cap, it's a no brainer; oh brainless wonder.

  • zero.risk13 by zero.risk13 Jul 30, 2014 5:58 PM Flag

    GTHP is now higher priced than ONCS, but the market cap is about 1/4 that of ONCS.

    ONCS will not have anything approved for at least 5 years.
    Considering that small biotechs always get a CRL on their first filing,
    You are probably looking a 7 years and if a P3 trial fails it could be 10 to 12 years.

    GTHP is approved in the EU and several other international markets.
    The PMA was refiled with the FDA a few days ago.
    So approval should come in a few months.

    The HPV testing market is huge.
    Over 60 million pap smear tests are taken annually in the US.
    GTHP has superior technology.
    Biophotonics is more accurate and produces immediate test results.
    Swabs do not need to be sent to a lab.

    Revenues are starting to accelerate.
    The high margin disposables will beef up the profit margins.

    GTHP is on the launch pad.
    ONCS is bobbing on a dangerous sea and could capsize.

  • Reply to

    Merck profits double!

    by ooo_key_doke Jul 29, 2014 8:34 AM
    zero.risk13 zero.risk13 Jul 29, 2014 9:14 AM Flag

    Heck, Merck could buy out GTHP which has an APPROVED product for a multi-billion dollar market in cancer detection. The market cap is only $35M. Why spend over $100M for something that may never be approved?

    It's easy spending other people's money. If you had $200M would you blow it on a P2 long shot or on a company with a product that is producing growing revenues?

  • "Guided Therapeutics, Inc. (GTHP) today announced that it has filed an amendment to its premarket approval (PMA) application with the U.S. Food and Drug Administration (FDA) for the LuViva® Advanced Cervical Scan. The FDA has 180 days to respond to the amendment.

    The company has regulatory approval to sell LuViva in Europe with the Edition 3 CE mark, and has marketing approvals from COFEPRIS in Mexico, Health Canada and Singapore Health Sciences Authority, among others. Additionally, expansion efforts are ongoing in the Middle East, Asia and Latin America."

    GTHP's market cap is $35M and its product is approved internationally and will be approved in the US in a few months.
    ONCS' market cap is $125M and it has nothing approved, is years away from approval, if ever.

    The market is huge for GTHP's biophotonic cervical cancer scan
    Over 60M pap smear tests are taken annually in the US alone.

    "LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which may result in eliminating costly, painful and unnecessary additional testing."

  • Reply to

    A Good Time to Switch to GTHP

    by zero.risk13 Jul 14, 2014 9:42 AM
    zero.risk13 zero.risk13 Jul 17, 2014 4:22 PM Flag

    My GTHP was up today.
    Off to the races on PMA filing this month.

  • Reply to

    GTHP Will Soon Be Higher Priced

    by zero.risk13 Jul 15, 2014 10:17 AM
    zero.risk13 zero.risk13 Jul 16, 2014 1:56 PM Flag

    BINGO!
    GTHP is .49, ONCS is .48.

    You are riding the wrong horse.
    Actually, you are riding a broken down nag and I'm riding a stallion.

    Approved always trumps nothing approved for years to come, if ever.

SNTA
4.00-0.03(-0.74%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Burger King Worldwide, Inc.
NYSEFri, Aug 29, 2014 4:02 PM EDT
Synaptics Inc.
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT